July 2009 Volume 6 Number 7
Visit Nature Reviews Clinical Oncology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=43&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Clinical Oncology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=48&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=67&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 8.217*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Nature Reviews Clinical Oncology brings all the qualities of the top-ranked
life sciences series to the clinical sciences and is a valuable resource
for practicing physicians and clinical academics.
Visit Nature Reviews Clinical Oncology online at
http://links.ealert.nature.com/ctt?kn=40&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
and keep up-to-date with the latest advances in oncology.
=====================================================================
----------------------
EDITORIAL
----------------------
The most important news at ASCO 2009
Vincent T. DeVita, Jr
p371 | doi:10.1038/nrclinonc.2009.93
http://links.ealert.nature.com/ctt?kn=76&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Genetics: TP53 mutations predict response to cetuximab
p373 | doi:10.1038/nrclinonc.2009.75
http://links.ealert.nature.com/ctt?kn=52&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Mutation status and treatment response
p374 | doi:10.1038/nrclinonc.2009.80
http://links.ealert.nature.com/ctt?kn=88&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Targeted therapies: KRAS wild-type tumors benefit from cetuximab
p374 | doi:10.1038/nrclinonc.2009.81
http://links.ealert.nature.com/ctt?kn=34&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Surgical oncology: Markers of long-term survival in pancreatic cancer
p375 | doi:10.1038/nrclinonc.2009.74
http://links.ealert.nature.com/ctt?kn=66&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Maintenance rituximab prolongs PFS
p375 | doi:10.1038/nrclinonc.2009.77
http://links.ealert.nature.com/ctt?kn=45&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Screening: Ovarian cancer: feasibility of early detection
p375 | doi:10.1038/nrclinonc.2009.79
http://links.ealert.nature.com/ctt?kn=80&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Imaging: FDG-PET/CT: early predictor of treatment response in soft-tissue
sarcoma
p376 | doi:10.1038/nrclinonc.2009.76
http://links.ealert.nature.com/ctt?kn=30&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Imaging: FDG-PET accurately detects distant disease
p376 | doi:10.1038/nrclinonc.2009.78
http://links.ealert.nature.com/ctt?kn=3&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Surgery: Stereotactic radiosurgery alone to treat brain metastases
Laura A. Vallow
p377 | doi:10.1038/nrclinonc.2009.84
Brain metastases are a challenge for the oncologist, with 20-40% of cancer
patients developing intracranial metastases during the course of their
illness. The incidence of brain metastases is increasing as a result of
improvements in systemic therapy and imaging capabilities, and increased
use of screening. Brain metastases pose not only a risk to mortality but
also a risk of neurologic, cognitive and emotional difficulties.
http://links.ealert.nature.com/ctt?kn=85&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Targeted therapies: Cetuximab, chemotherapy and KRAS status in mCRC
Sharlene Gill and Richard M. Goldberg
p379 | doi:10.1038/nrclinonc.2009.83
The first-line treatment for patients with unresectable metastatic
colorectal cancer is chemotherapy in combination with bevacizumab.
Emerging evidence, however, suggests that the addition of cetuximab-an
anti-EGFR monoclonal antibody-to chemotherapy might be beneficial to
patients with wild-type KRAS tumors.
http://links.ealert.nature.com/ctt?kn=25&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Hematology: ASCT in follicular lymphoma
Jennifer R. Brown and Arnold S. Freedman
p380 | doi:10.1038/nrclinonc.2009.87
The use of autologous stem-cell transplantation in the treatment of
follicular lymphoma remains controversial. Results from the GOELAMS trial
show a higher progression-free survival rate in patients treated with
autologous stem-cell transplantation compared to those treated with
chemotherapy.
http://links.ealert.nature.com/ctt?kn=14&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Surgery: Role of lymphadenectomy in the staging of endometrial cancer
Kimberly E. Resnick, David E. Cohn and Jeffrey M. Fowler
p382 | doi:10.1038/nrclinonc.2009.88
Pelvic lymphadenectomy offers no therapeutic benefit to women diagnosed
with early-stage endometrial cancer according to a new study.
Lymphadenectomy can only be recommended as part of a clinical trial in
this disease setting; however, it can offer valuable staging information
in those with advanced disease.
http://links.ealert.nature.com/ctt?kn=50&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Screening: Cervical cancer in rural India
Anthony B. Miller
p384 | doi:10.1038/nrclinonc.2009.85
A study of cervical cancer screening in 52 villages in India has shown
that a single round of human papillomavirus testing was linked to a
significant reduction in the number of deaths from cervical cancer,
compared with other screening methods. This has implications for primary
screening in low-resource settings.
http://links.ealert.nature.com/ctt?kn=72&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Surgery: Apples and oranges: the low and mid versus the upper rectum
Martin Weiser and Leonard Saltz
p385 | doi:10.1038/nrclinonc.2009.86
The role of laparoscopic resection for rectal cancer is currently unclear,
with little supportive evidence from randomized trials. A study by Ng
et al. in a large series of patients with rectal cancer has shown that
laparoscopic resection is safe with good long-term outcomes.
http://links.ealert.nature.com/ctt?kn=68&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Molecular targets for treatment of inflammatory breast cancer
Hideko Yamauchi, Massimo Cristofanilli, Seigo Nakamura, Gabriel N.
Hortobagyi and Naoto T. Ueno
Published online: 26 May 2009
p387 | doi:10.1038/nrclinonc.2009.73
The long-term outcome for patients with inflammatory breast cancer is
poor despite advances in combined-modality treatment. Treatments
targeting the vasculolymphatic pathway have shown potential and therapies
targeting cell proliferation pathways are also promising. The authors
of this Review discuss the biology of inflammatory breast cancer and
potential molecular targets.
Abstract: http://links.ealert.nature.com/ctt?kn=29&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=74&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Anticancer strategies involving the vasculature
Victoria L. Heath and Roy Bicknell
Published online: 07 May 2009
p395 | doi:10.1038/nrclinonc.2009.52
Understanding the process of tumor angiogenesis and ways to modify this
is a key point in the fight against cancer. This Review explores the
current status of vascular-disrupting strategies, discusses how
anti-VEGF-based anti-angiogenic therapies can be combined with conventional
chemotherapy and radiotherapy, and highlights potential future targets
for therapeutic intervention.
Abstract: http://links.ealert.nature.com/ctt?kn=38&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=28&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
Lisa Pleyer, Alexander Egle, Tanja Nicole Hartmann and Richard Greil
Published online: 02 June 2009
p405 | doi:10.1038/nrclinonc.2009.72
The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic
chemotherapy; however, CLL is still an incurable disease with resistance
to therapy developing in a majority of patients. This Review summarizes
the progress made in understanding the biological basis of CLL pathogenesis
and other aspects of CLL biology, and describes novel treatment strategies
that have also been exploited in current clinical trials.
Abstract: http://links.ealert.nature.com/ctt?kn=57&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=49&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Surgical management of pancreatic endocrine tumors
Volker Fendrich, Jens Waldmann, Detlef K. Bartsch and Peter Langer
Published online: 09 June 2009
p419 | doi:10.1038/nrclinonc.2009.82
Pancreatic endocrine tumors (PETs) represent an important subset of
pancreatic neoplasms. Patients with completely resected tumors generally
have a good prognosis, and an aggressive surgical approach in patients
with advanced disease may also prolong survival. The authors of this
Review discuss the current surgical management strategies for treating
PETs, focusing on insulinomas, gastrinomas and nonfunctional PETs.
Abstract: http://links.ealert.nature.com/ctt?kn=62&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=20&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
A stepwise approach to the management of metastatic midgut carcinoid
tumor
Sanjeev Bhattacharyya, Dorothy M. Gujral, Christos Toumpanakis, Gilles
Dreyfus, Brian R. Davidson, Joseph Davar and Martyn E. Caplin
p429 | doi:10.1038/nrclinonc.2009.70
The authors present a case of a 48-year-old man with a history of diarrhea,
flushing and upper abdominal pain who was subsequently diagnosed with
metastatic carcinoid tumor. The authors discuss the importance of a
stepwise approach in a multi-disciplinary team setting to provide
effective patient care.
Abstract: http://links.ealert.nature.com/ctt?kn=22&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=81&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Clinical Oncology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
- Links to the European School of Oncology, including e-grandrounds
http://links.ealert.nature.com/ctt?kn=40&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=33&m=33476114&r=MTc2NDg2OTc4MQS2&b=2&j=NTIzMTI4NDQS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
